I
Ionova Life Science
A biomedical company that leads technological innovation and benefits human health
About Ionova Life Science
Ionova Life Science is a clinical-stage biotechnology company located in the Guangdong-Hong Kong-Macao Greater Bay Area of China, established in November 2016. The company was founded by Dr. Yongkui Sun, a scientist with over 20 years of experience in research and development at Merck Research Laboratories and a member of the US National Academy of Engineering. Dr. Sun's extensive background in the pharmaceutical industry underpins the company's core mission.
The firm concentrates on the development of a new generation of targeted immunotherapies for cancer treatment. Its operational strategy is centered on translating discoveries in basic biomedical research into novel drugs with distinct clinical advantages. Ionova's business model involves in-house drug discovery and development, supplemented by collaborations with academic and industrial partners through its research division, the Touchstone Translational Research Institute. The company's revenue generation is tied to the progression of its drug candidates through clinical trials and eventual commercialization, a long-term strategy typical of the biotechnology sector. This is supported by significant venture capital funding.
Ionova Life Science has built a robust pipeline of drug candidates aimed at combating cancers and addressing cancer resistance. A key focus area since its inception has been research into the tumor microenvironment and immunoregulation. The company's product development strategy combines immunotherapy with targeted therapy to create synergistic effects. One of its leading candidates, INV-1120, has entered Phase I clinical trials in the United States. The company has secured substantial funding to advance its portfolio, including a $17 million Series A in October 2019 and a $100 million financing round in August 2021, which supports the progression of its preclinical and clinical oncology candidates.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Aug 2021 | $100M | $400M | Lilly Asia Ventures · Shenzhen Capital Group · Tsing Capital · Dyee Capital | — |
| SERIES AOther financing | Oct 2019 | $18M | $71M | Dyee Capital · Lilly Asia Ventures | — |
Growth signals
Latest recorded traffic for Ionova Life Science is 1.5K monthly website visits, up 64.8% over the last three months. Ionova Life Science's team grew 7.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ionova Life Science in the Shenzhen ecosystem
The Ionova Life Science office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Dyee Capital
Lilly Asia Ventures
Shenzhen Capital Group- TCTsing Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ionova Life Science on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ionova Life Science’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








